Analysts discovered that the Quris Bio-AI Clinical Prediction Platform enhances drug improvement course of agility, shortens discovery timelines, will increase drug security, and improves drug pipeline diversification alternatives
SAN ANTONIO, Aug. 31, 2022 /PRNewswire/ — Frost & Sullivan not too long ago researched the synthetic intelligence (AI)-enabled drug security prediction know-how trade and, primarily based on its findings, acknowledges Quris with the 2022 Europe Technology Innovation Leadership Award. The modern Quris Bio-AI Clinical Prediction Platform is the primary AI breakthrough to shut the medical prediction hole by successfully predicting which drug candidates will work safely in people.
Get entry to extra particulars on the award multi-media web page – https://best-practices.frost.com/quris-technologies/
“Quris AI Chip-on-Chip platform, unlike other AI-pharma solutions focusing on drug discovery, better indicates which drug candidates will safely work in humans. It uses AI to predict a drug’s safety, and hence its ability to succeed, particularly in Phase 1 trials, thus avoiding the high costs of failed clinical trials for pharmaceutical companies,” stated Supriya Lala Kundu, a Best Practices Research analyst at Frost & Sullivan.
The firm’s platform scales to suit the intricacies of medical prediction, requiring machine studying (ML) fashions to routinely run an unlimited variety of organic Patients-on-a-Chip experiments for AI coaching. Quris’s AI Chip-on-Chip know-how leverages a patented course of to check hundreds of recognized secure and unsafe medicine on hundreds of miniaturized Patients-on-a-Chip making use of an automatic, high-throughput system. Similarly, next-generation nano-sensors allow steady response monitoring from every miniaturized organ to those medicine. Moreover, steady knowledge technology additional trains the ML classification algorithm, making it extremely predictive of medical security and enabling it to higher discern the toxicity degree of recent drug candidates throughout testing. The modern and ground-breaking platform simulates a pure human physique’s response to novel molecules with out counting on inaccurate animal testing – decreasing animal cruelty throughout pre-clinical experimentation as a consequence of its potential to restrict dependence on animal testing.
Ashish Kaul, an trade analyst for Frost & Sullivan, stated, “Unlike other organ-chip devices with limited ability to run millions of experiments, the Quris platform is highly scalable, enabling massive experiments to run cost-effectively and train the AI, thereby revolutionizing the pharmaceutical industry. Additionally, the platform can scale up to 1,000 drugs across all therapeutics, notably oncology, rare disease, and the blood-brain barrier.”
Quris stands out from opponents primarily based on its dedication to innovation and creativity whereas reaching industrial success. In addition to its drug security prediction pharma companies, Quris additionally has a drug pipeline and supplies customized medication companies. The firm has a workforce of scientists, know-how consultants, medical pioneers, and seasoned administration professionals with a monitor file of seamless execution. Its robust mental property portfolio protects its pioneering know-how, including worth relative to its development potential, thus securing a aggressive benefit. Its first AI-based Fragile-X drug is getting ready for medical testing later in 2022. Additionally, the corporate has established stem cell facilities worldwide to offer customized medication companies, additional validating its platform and enabling it to develop via strategic partnerships with trade and analysis institutes.
“Recognition by the Frost & Sullivan team further validates our mission to completely rethink drug development and solve the biggest drug discovery challenge of our era – using AI clinical prediction to remove longstanding barriers for the entire pharma industry. Allowing the efficient discovery of new drugs and the repurposing/personalization of existing drugs, Quris will help pharma companies avoid the tremendous risks and costs of failed clinical trials and end the reliance on ineffective animal testing,” added Quris Founder and CEO Isaac Bentwich.
Each yr, Frost & Sullivan presents this award to the corporate that develops a product with modern options and performance that’s gaining speedy acceptance out there. The award acknowledges the standard of the answer and the client worth enhancements it permits.
Frost & Sullivan Best Practices awards acknowledge firms in numerous regional and international markets for demonstrating excellent achievement and superior efficiency in management, technological innovation, customer support, and strategic product improvement. Industry analysts examine market contributors and measure efficiency via in-depth interviews, analyses, and intensive secondary analysis to determine finest practices within the trade.
For six many years, Frost & Sullivan has been world-renowned in serving to traders, company leaders, and governments navigate financial adjustments and determine disruptive applied sciences, Mega Trends, new business fashions, and corporations to motion, leading to a steady move of development alternatives to drive future success. Contact us: Start the dialogue.
Kristen Moore
P: 1.210.247.3823
E: [email protected]
About Quris
Quris, the world’s first Bio-AI clinical-prediction platform ensures the protection and efficacy of recent medicine. Revolutionizing the drug improvement course of, the corporate is pioneering medical trials on chips – testing hundreds of novel drug candidates on a whole lot of miniaturized “patients-on-a-chip”. Its totally automated, self-training AI platform precisely predicts medical security and efficacy for novel medicine sooner and extra affordably than ever earlier than – all whereas minimizing animal testing. Dual-headquartered in Boston and Israel and backed by strategic biotech and large knowledge traders, Quris is led by a confirmed workforce of AI and medical analysis powerhouses who’re already getting ready its lead discovery for medical trials. For extra info, go to www.quris.ai.
Erica Camilo
P: 1.610.639.5644
E: [email protected]
Photo – https://mma.prnewswire.com/media/1887364/Quris_Technologies_Award_Logo.jpg
